
Webinar: Michael Gilhooley, Optogenetics
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Search results
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
We recently received an update on the latest research into Charles Bonnet Syndrome from Dr Jasleen Jolly as part of a Retina UK podcast about visual hallucinations.
Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.
New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.
In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.
jCyte have released additional preclinical data regarding jCell
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
There are many other ways you can support Retina UK, including raising donations as you shop and sell online, and donating your foreign currency, stamps or shares.